Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Tertiary objectives.
View:
Post by tamarindo1 on Apr 27, 2021 12:07pm

Tertiary objectives.

Heck, most old guys experience many of these kinds of adverse effects on a daily basis.


In support of the tertiary objective, all patients have experienced some transient grade 1 or grade 2 AEs (e.g.: bladder spasms, constipation, urge incontinence, fatigue, urinary frequency, hematuria, penile discomfort, urinary urgency, pain, urinary tract infections and other) where > 80% have completely resolved with 180 days. One patient was diagnosed with urosepsis (infection in the urinary tract) that co
Comment by enriquesuave on Apr 27, 2021 12:25pm
Uro sepsis is one of the side effects of simply doing a cystoscope exam.  
Comment by enriquesuave on Apr 27, 2021 12:41pm
I wonder when will the partial responders be ruled out as either CR or not.  So far even at 6 months they are showing a negative cystoscope ( no visible cancer) but a positive urine cytology.  They have to use a uretoscope to examen for possible UTUC.   This is a very good sign that they are still showing no cancer with cystoscope after 6 months.  Numbers can go up dramatically ...more  
Comment by enriquesuave on Apr 27, 2021 12:49pm
It seems possible that either 13 or 14 or 15 was the patient who died as this patient showed negative urine cytology eliminating sign of cancer at 30 days, but unfortunately did not live long enough to get to 3 months exam. Just guessing here, as we only now learned of this outcome. If this was the case it would have been 3 on 3.  Just a guess.
Comment by stocksnbonds458 on Apr 27, 2021 1:04pm
Enrigue your well thought out and technically accurate posts are much appreciated by all I am sure! I just wish it wasn't necessary for you to do this, to clear up the ambiguity and confusion introduced by Theralase's press releases. Maybe patients #5 and # 6 from phase 1 should be writing these Quarterly newsletters for now on, perhaps as a testament to almost 2 years cancer free.
Comment by enriquesuave on Apr 27, 2021 8:40pm
What I wrote earlier seems to make sense. Patients 13 and on got an Optimized Treatment.  There are 3 more patients pending for 90 days data (ie. patients 16, 17,18). Hence of 13,14 and 15 ,  2 are CR and unfortunately 1 died unrelated to treatment.  They do indicate in Quarterly that the patient who died had negative Urine cytology at 30 days ( hence no sign of cancer)and would ...more  
Comment by tdon1229 on Apr 27, 2021 11:12pm
  Enrique, i wouldn't be too quick to dismiss the death as unrelated.  True, I think it's plain to see it's not from exposure to either the TLD-1433 or to the light source or the activation.  However, filling the bladder and holding it for an hour during instillation, with successive prerinses and post rinses, results in back pressure on the kidneys.  That can ...more  
Comment by fredgoodwinson on Apr 28, 2021 4:57am
At first glance I couldn`t understand why the optimised treatment had apparently elicited no response whatsoever in one of the patients. TBH with my faith in the tech it came as a real shock.   Of course this is the patient who sadly died. Since there was no cancer in his/her urine at 30 days` I believe that had he/she lived we might still be on track for 100% CRs with the 6 most ...more  
Comment by enriquesuave on Apr 28, 2021 8:00am
Now we can say that any and all treatments which require drug instillations can cause the same issue and is actually seen as a side effect of all of the other competition. 
Comment by Pandora on Apr 27, 2021 1:47pm
And there is a "good" point. This is one of the only drugs presenting side effects that does not include diarreah! ----  although it is the other channel. :-)) That's gotta be a plus for the old guys regardless. Infections = c-diff.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250